Product Information
SUMATRIPTAN SUCC 100 MG TABLET is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.4388 per EA under NDC 64980066291. Its NADAC has been published 54 times since Sep 24, 2025.
FDA first approved this application on Dec 31, 2024. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The Low Outlier badge above means this manufacturer's average price in the sumatriptan market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
100 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
64980066291
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SUMATRIPTAN SUCCINATEApproval Type
Generic (ANDA)
FDA Application
ANDA219036FDA Approved
12/31/2024
TE Code
AB
On Market Since
5/5/2025
Pharmacological Classes
Price Statistics
The NADAC for SUMATRIPTAN SUCC 100 MG TABLET has been published 54 times since Sep 24, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4388 per EA |
|---|---|
| All-time high | $0.4721 (Jan 14, 2026) |
| All-time low | $0.4309 (Aug 19, 2026) |
| 52-week high | $0.4721 |
| 52-week low | $0.4309 |
| Median price | $0.4390 |
| Average price | $0.4458 |
| Largest weekly change | -3.4% (Feb 18, 2026) |
| Weeks tracked | 54 |
| Tracking since | Sep 24, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
sumatriptan market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SUMATRIPTAN SUCC 100 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for SUMATRIPTAN SUCC 100 MG TABLET, manufactured by Rising Pharma Holdings Inc., is $0.4388 per EA (NDC 64980066291), effective Sep 30, 2026.
How has the price of SUMATRIPTAN SUCC 100 MG TABLET changed over time?
Over the history we have for it, the NADAC for SUMATRIPTAN SUCC 100 MG TABLET has held within roughly two percent of its current level. It has been tracked across 54 weekly CMS publications since Sep 24, 2025.
What are the highest and lowest recorded NADAC prices for SUMATRIPTAN SUCC 100 MG TABLET?
Since Sep 24, 2025, the NADAC for SUMATRIPTAN SUCC 100 MG TABLET has ranged from a low of $0.4309 (Aug 19, 2026) to a high of $0.4721 (Jan 14, 2026), with a median of $0.4390 per EA.
Are there cheaper alternatives to SUMATRIPTAN SUCC 100 MG TABLET?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as SUMATRIPTAN SUCC 100 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures SUMATRIPTAN SUCC 100 MG TABLET?
SUMATRIPTAN SUCC 100 MG TABLET (NDC 64980066291) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.